SCNI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SCNI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Scinai Immunotherapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.38 Mil. Scinai Immunotherapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $19.43 Mil. Scinai Immunotherapeutics's annualized EBITDA for the quarter that ended in Sep. 2023 was $-7.83 Mil. Scinai Immunotherapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -2.53.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Scinai Immunotherapeutics's Debt-to-EBITDA or its related term are showing as below:
During the past 12 years, the highest Debt-to-EBITDA Ratio of Scinai Immunotherapeutics was -1.28. The lowest was -74.86. And the median was -2.05.
The historical data trend for Scinai Immunotherapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scinai Immunotherapeutics Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Debt-to-EBITDA | Get a 7-Day Free Trial | -1.28 | -1.42 | -74.86 | -2.79 | -2.05 |
Scinai Immunotherapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Debt-to-EBITDA | Get a 7-Day Free Trial | -2.11 | -1.90 | -1.91 | -2.51 | -2.53 |
For the Biotechnology subindustry, Scinai Immunotherapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Scinai Immunotherapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Scinai Immunotherapeutics's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Scinai Immunotherapeutics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.382 | + | 21.16) | / | -10.499 | |
= | -2.05 |
Scinai Immunotherapeutics's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (0.382 | + | 19.425) | / | -7.828 | |
= | -2.53 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.
Scinai Immunotherapeutics (NAS:SCNI) Debt-to-EBITDA Explanation
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
Be Aware
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Samuel J Moed | director | BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543 |
Mark Germain | director, other: Chairman | WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022 |
Uri Ben-or | officer: Chief Financial Officer | C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Yael Margolin | director | 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268 |
Adi Raviv | director | STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601 |
Morris C Laster | director | 11 REUVEN SHARI ST., JERUSALEM L3 9724611 |
Tamar Ben-yedidia | officer: Chief Scientist | 6 HAZIT ST., MAZKERET BATIA L3 7685421 |
Avner Rotman | director | 21 EISENBERG ST., REHOVOT L3 7628905 |
Amir Reichman | director, officer: Chief Executive Officer | 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500 |
Elad Mark | officer: Chief Operating Officer | 27 HAILANOT, HERZLIYA L3 4631214 |
George Lowell | director | 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317 |
Jay Green | director | 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6 |
From GuruFocus
By Marketwired • 09-19-2023
By PRNewswire • 01-04-2024
By Stock market mentor Stock market mentor • 01-05-2023
By Stock market mentor Stock market mentor • 01-23-2023
By Tiesvg Tiesvg • 12-30-2022
By PRNewswire • 11-29-2023
By ACCESSWIRE ACCESSWIRE • 12-21-2022
By Marketwired • 09-11-2023
By Marketwired • 11-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.